ROYAL BRISBANE AND WOMEN'S HOSPITAL

Australian-First "Seek-and-Destroy" Cancer Therapy Begins Human Trials Targeting CDCP1 Protein

- A groundbreaking radioactive therapy targeting the CDCP1 protein in cancer cells has begun its first human trial in Australia, with a 69-year-old Brisbane woman becoming the first patient to receive the treatment. - The therapy, developed over 24 years by Professor John Hooper, uses an innovative antibody that binds to CDCP1 found in ovarian, bladder, and other common cancers to deliver targeted radiotherapy. - Up to 45 patients with ovarian and bladder cancer will participate in the trial, which aims to provide exceptionally accurate imaging of metastasizing cancer and potentially become the gold standard treatment for multiple cancer types. - The research represents a collaboration between Mater Research, The University of Queensland, CSIRO, and other institutions, with ovarian cancer having a five-year survival rate of just 49 percent.